דקסימון 100

Country: Իսրայել

language: եբրայերեն

source: Ministry of Health

active_ingredient:

CICLOSPORIN

MAH:

DEXCEL LTD, ISRAEL

ATC_code:

L04AA01

pharmaceutical_form:

קפסולות

composition:

CICLOSPORIN 100 MG

administration_route:

פומי

prescription_type:

מרשם נדרש

manufactured_by:

DEXCEL LTD, ISRAEL

therapeutic_group:

CYCLOSPORIN

therapeutic_area:

CYCLOSPORIN

therapeutic_indication:

Prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. May also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. Bone marrow transplantation. Endogenous uveitis. Severe psoriasis above age 16 that did not respond to other treatment. Atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. Rheumatoid arthritis: Severe cases in which standard treatments are ineffective or inappropriate. Nephrotic syndrom type MCD (minimal change disease) in cases where conventional therapy has failed.

leaflet_short:

1. התרופה תינתן לטיפול במושתלי כליה, או מושתלי כבד, או מושתלי לב, או מושתלי ריאה; 2. הטיפול בתרופה ייעשה לפי מרשם של רופא מומחה באימונולוגיה קלינית או רופא מומחה העוסק בתחום ההשתלות.

authorization_date:

2021-12-31

PIL

" )
(
–
1986
®
25 ,
50
,
100
" ,
:
)
Ciclosporin
(
25
,
50
100
.
"
–
6
"
"
2
"
"
.
.
.
.
,
.
.
.
1
. ?

,
.

.

)
(
.)
Endogenous uveitis
(

(Minimal Change Disease MCD
(
.

.

16
.

)
atopic dermatitis
(
8
,
.
:
.
,
.
.
,
)
(
,
.
2
.
,
/
.
-
.
.
.
:

(
)
(
)
(
6
.)

(
Hypericum perforatum
–
St. John's Wort
.)

(
Dabigatran etexilate
)
( )
(
Bosentan
(
)
Aliskiren
.)
( )
,
,
.
.
, :

,
.
.

.

.
.

.
.

.
,
.

.

.)
Gout
(

.
,
.
.
,
,
.
UV
.
:

.

.

.

.

.

.
(
)
,
.
,
.
"
."
:

-
.

.

.

.
.
,
(
:
,
,
,
'
,)
:

)
(
.

.

.

.
,
.
,
.
.
'
(
Behcet
’
s uveitis
)
,
(
:
,
,
,
"
"
,
,
,
,
,
,
.)
,
UVB
)
)
.
.
.
,
(
65
)
.
.
65
,
. , , ,
.
:

,
,
.

.
,
.

(
.
)
.
o
:
)
,
,)
-
,
(
)
,
(
:
,
,
,
,)
(
,)
,
(
,)
(
)
,
(
,)
(
,
,)
,
(
C
)
,
)
(
.
o
:
(
,)
(
,
,)
(
,)
-
(
,
,)
St. John's wort
,
(
,)
)
,)
(
.)
-

,
-
,
,
(
,)
-
B
,
,
,
(
-
H2
,)
,
(
,)
(
.)

,
.
,
.

(
,)
(
HMG-CoA
(
,)
(
,
,)
-
,)
,
(
,)
.)
(

(
)
(
.)
(
,)
.
.
.
.
.
.
,
.
,
.
.
,
,
.
C
(
C
)
C
.
C
,
.
C
.
,
.
.
,
.
.
)
(
,
25
,
"
50
,
"
100
"
32
,
"
65
,
"
129
,
"
-
14.2%
.
500
"
-
17
"
7
.
"
.
.
,
.)
(
,
.
3
.
?
.
.
.
.
.
,
.
.
,
.
.
,
,
.
.
,
.
,
,
.
,
.
,
.
.
.
.
.
/
/
.
,
,
,
.
8
.
.
,
.
,
.
.
,
,
.
.
!
.
.
.
. ! .
. ,
.
4
.
,
.
.
.
:
:

,
,
,
.
,
.

,
,
,
,
,
progressive multifocal leukoencephalopathy (PML)
.

:
,
,
,
,
,
,
,
,
,
,
,
,
.

(
-
benign intracranial
hypertension
)
.

,
,
.

.

.
,
,
,
(
)
,
,
,
,
.
:)
(
,
,
,
,
,
.
,
.
(
-
1-10
100
:)
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
)
(
,
,
.
,
.
(
-
1-10
1,000
:)
,
,
,
,
,
,
,
.
,
,
,
,
,
.
,
.
(
-
1-10
10,000
:)
,
,
,
,
,
,
/
,
,
;
,
,
,
)
(
,
,
,
.
,
.
(
10,000
:)
.
,
.
:)
(
,
,
,
,
,
,
,
;
,
;
,
;
,
.
,
. ,
. ,
:
.
:
"
"
(
www.health.gov.il
)
,
:
https://sideeffects.health.gov.il
5
.
?

!
/
.
.

.
.

:
-
25°C
.
/
.

.
.

.
.
.
6
.
:
Ethyl lactate, gelatin, macrogolglycerol hydroxystearate, polysorbate
20, sorbitan oleate,
triglyceri